TB-500 | Luxbae Peptide Therapy

Home › Peptides › TB-500
Thymosin Beta-4 Fragment

TB-500 Thymosin Beta-4 Fragment

A synthetic fragment of thymosin beta-4 studied for cell migration, angiogenesis, and tissue repair.

Book Free ConsultationCall 310.299.4444

What TB-500 actually is

TB-500 is a synthetic version of the active region of thymosin beta-4 — a 43-amino-acid actin-binding protein abundant in platelets and wound fluid. Goldstein and colleagues characterized its actin-sequestering function and its role in cell migration, angiogenesis, and repair after tissue injury.1

In animal models of myocardial infarction, dermal wounding, and ocular injury, thymosin beta-4 has accelerated repair via increased angiogenesis, reduced apoptosis, and enhanced cell migration.2 TB-500 is the most commonly prescribed synthetic form in peptide practice; we use it most often alongside BPC-157.

At Luxbae, TB-500 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Actin binding and cell migration

Sequesters G-actin, promotes cell migration and tissue repair signaling, drives angiogenesis in wound models.1

What the research shows

Cell migration. Promotes migration of fibroblasts, endothelial cells, and stem cells to injury sites.1

Angiogenesis. Drives capillary formation in wound and ischemia models.2

Anti-inflammatory. Reduces inflammatory burden in cardiac injury models.3

Side effects: Injection-site reactions, transient flushing, mild lethargy at high doses.

FDA note: TB-500 is not FDA-approved. Investigational; prescribed under physician supervision.

TB-500 FAQ

How is this different from BPC-157?
Different mechanism — actin sequestration and cell migration, not VEGF-mediated angiogenesis primarily.

Why pair with BPC-157?
Orthogonal mechanisms — addressing repair from two distinct angles.

References

  1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51.
  2. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites. FASEB J. 2010;24(7):2144-2151.
  3. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-644.

Start your TB-500 protocol at Luxbae

Call 310.299.4444Book Online
Medical disclaimer: This is educational information, not medical advice. TB-500 is investigational and many uses are not FDA-approved; treatments at Luxbae are administered under medical supervision by Dr. Ernst von Schwarz. Individual results vary.
Scroll to Top